Georgia Life Sciences Statement on the Most Favored Nation Executive Order
Georgia is home to a dynamic and fast-growing life sciences industry—built on bold ideas, scientific risk-taking, and an unwavering commitment to improving patient outcomes. That progress depends on smart, forward-looking policies that support innovation, investment, and access to care.
The Most Favored Nation (MFN) policy outlined in this week’s Executive Order threatens to undermine those goals. By tying U.S. drug reimbursement to artificially low prices set by foreign governments, MFN would effectively import price controls from systems that frequently delay—or outright deny—patient access to new therapies.
This policy would have real and damaging consequences: stifling innovation, weakening our national leadership in biomedical R&D, and jeopardizing the survival of early-stage biotech companies that form the backbone of Georgia’s life sciences economy.
The cost of these short-sighted policies is not theoretical. It means fewer life-saving therapies making it to market—especially for patients with rare, complex, or life-threatening diseases. Studies have repeatedly shown that countries with strict price controls suffer from slower access to breakthrough treatments, if they receive them at all.
Georgia Life Sciences urges the Administration and Congress to reject policies that compromise patient care and biomedical progress. Instead, we must work together on balanced solutions that lower out-of-pocket costs for patients while preserving America’s innovation ecosystem. We remain committed to partnering with policymakers to ensure patients in Georgia—and across the country—continue to benefit from the scientific advances our sector delivers every day.
